A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes....

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) Vol. 10; no. 14; pp. 4823 - 4831
Main Authors: Oswald, Laura B., Arredondo, Brandy, Kadono, Mika, Martinez‐Tyson, Dinorah, Meade, Cathy D., Penedo, Frank, Antoni, Michael H., Soliman, Hatem, Costa, Ricardo L. B., Jim, Heather S. L.
Format: Journal Article
Language:English
Published: United States John Wiley & Sons, Inc 01.07.2021
John Wiley and Sons Inc
Wiley
Subjects:
ISSN:2045-7634, 2045-7634
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first